HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winer, J B Search for Related Content PubMed PubMed Citation Articles by Winer, J B

Guillain Barré syndrome

Department of Neurology, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK

Correspondence: Dr Winer j.b.winer{at}bham.ac.uk

Guillain Barré syndrome is one of the best examples of a post infectious immune disease and offers insights into the mechanism of tissue damage in other more common autoimmune diseases. Controlled epidemiological studies have linked it to infection with Campylobacter jejuni in addition to other viruses including cytomegalovirus and Epstein Barr virus. The syndrome includes several pathological subtypes, of which the most common is a multifocal demyelinating disorder of the peripheral nerves in close association with macrophages. Evidence from histological examination of peripheral nerve biopsy and postmortem samples suggests that both cell mediated and humoral mechanisms are involved in the pathogenesis. Immunological studies suggest that at least one third of patients have antibodies against nerve gangliosides, which in some cases also react with constituents of the liposaccharide of C jejuni. In the Miller Fisher variant of the disease, these antiganglioside antibodies have been shown to produce neuromuscular block, and may in part explain the clinical signs of that disorder. Treatment with both intravenous immunoglobulin and plasma exchange reduces the time taken for recovery to occur, although mortality remains around 8%, with about 20% of patients remaining disabled.

Key Words: Guillain Barré syndrome • Campylobacter jejuni • antiganglioside antibodies • intravenous immunoglobulin treatment • plasma exchange

This article has been cited by other articles:

				M. P. Kozminski Miller Fisher Variant of Guillain-Barre Syndrome: A Report of Case J Am Osteopath Assoc, February 1, 2008; 108(2): 51 - 52. [Full Text] [PDF]

				M. H. RAVINDRANATH, S. MUTHUGOUNDER, T. S. SARAVANAN, N. PRESSER, and D. L. MORTON Human Antiganglioside Autoantibodies: Validation of ELISA Ann. N.Y. Acad. Sci., June 1, 2005; 1050(1): 229 - 242. [Abstract] [Full Text] [PDF]

				M. L. Linenberger and T. H. Price Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications J Intensive Care Med, March 1, 2005; 20(2): 88 - 103. [Abstract] [PDF]

				X. Zhang and F. L. Kiechle Glycosphingolipids in Health and Disease Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 3 - 13. [Abstract] [Full Text] [PDF]

				T. Bowes, E. R. Wagner, J. Boffey, D. Nicholl, L. Cochrane, M. Benboubetra, J. Conner, K. Furukawa, K. Furukawa, and H. J. Willison Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barre Syndrome Infect. Immun., September 1, 2002; 70(9): 5008 - 5018. [Abstract] [Full Text] [PDF]